Alzheimer Disease
Baxter Initiates Phase III Trial for the Treatment of Alzheimer's Disease
Published in Medical Letter on the CDC and FDA, October 12th, 2008
Baxter Healthcare Corporation announced initiation of a Phase III clinical trial following U.S. Food and Drug Administration (FDA) review of its investigational new drug application to evaluate GAMMAGARD LIQUID [Immune Globulin Intravenous (IGIV)], marketed as KIOVIG in European Union, for the treatment of mild-to-moderate Alzheimer's disease. This trial is expected to be the first of two pivotal Phase III trials required to support filing for regulatory approval for GAMMAGARD LIQUID as a potential treatment for the disease.
The Phase III trial is a prospective, 18-month, randomized, double-blind, placebo-controlled, two dose-arm, parallel study in 360 subjects of both...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA
More Articles from Medical Letter on the CDC and FDA
- Massachusetts General Hospital
Study confirms benefit of combination therapy for Alzheimer's disease - Anxiety Disorders
Labopharm Submits New Drug Application to FDA for DDS-04A to Treat Major Depression - Celsion Corporation
Celsion Provides Update on Its Global Pivotal Phase III Primary Liver Cancer Trial - Endoscopy
Study Published in Gastrointestinal Endoscopy Features Computer-Assisted Personalized Sedation (CAPS) - Obesity and Diabetes
First Reported Head-to-Head Study Showed BYETTAŽ (exenatide) Injection Provided Greater Reduction in Post-Meal Glucose Levels Than Januvia (sitagliptin) in Patients With Type 2 Diabet - Pneumococcal Disease
Major Adult Vaccine Clinical Trial for Pneumonia Prevention Begins - More from this issue of Medical Letter on the CDC and FDA
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
